$ABEO

O'Malley Brendan M. sold $60K of ABEO

O'Malley Brendan M. (SVP, Chief Legal Officer) sold 11,131 shares of ABEONA THERAPEUTICS INC. (ABEO) at an average of $5.36 ($5.30–$5.43) across 2 trades over 2026-06-08 to 2026-06-09.

Original reporting
SEC EDGAR · O'Malley Brendan M.
Published Jun 10, 2026, 12:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
high confidence
Mentioned
$ABEO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The only new information is the insider’s sale details (shares, prices, and post-transaction holdings). No guidance, trial, financing, or regulatory updates are provided.

02

Market read

Traders may note the insider sale, but the modest value and lack of additional catalysts make it unlikely to drive sustained repricing by itself.

03

What to watch

Insider sales can be driven by tax, diversification, or personal liquidity needs; without accompanying company news, the signal-to-noise is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-09T20:32:56-04:00 (covers trades 2026-06-08 to 2026-06-09)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for ABEONA THERAPEUTICS INC.

Company-level read

Ticker impact

$ABEONeutralHigh confidence
Context

ABEO disclosed an insider open-market sale by SVP/Chief Legal Officer Brendan M. O'Malley totaling about $59.6K across two trades (6/8–6/9).

Expected impact

Low near-term impact; any reaction is likely noise unless paired with other negative company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with modest size and no 10b5-1 plan indicated; it does not include new operational, financial, or regulatory facts.

Market effects

Minimal—single-company insider sale without sector-wide datapoints.

None indicated.

None indicated.

Counterpoint

Because the insider did not cite a 10b5-1 plan, some traders may read it as discretionary selling rather than scheduled diversification—though the dollar amount remains small.

Key entities

  • ABEO

    Abeona Therapeutics Inc., the company whose insider transaction was reported.

  • Brendan M. O'Malley

    SVP, Chief Legal Officer who sold 11,131 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.